Pan­cre­at­ic can­cer study fail­ure crip­ples a Mer­ri­mack drug, forc­ing a coup de grâce and pipeline re­treat

Eigh­teen months af­ter Mer­ri­mack $MACK re­struc­tured, sell­ing off its one mar­ket­ed drug, switch­ing out CEOs and cir­cling the wag­ons around three key can­cer drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA